Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.
FEBS J. 2024 Jan;291(1):10-24. doi: 10.1111/febs.16923. Epub 2023 Aug 11.
The protease A Disintegrin And Metalloproteinase 17 (ADAM17) plays a central role in the pathophysiology of several diseases. ADAM17 is involved in the cleavage and shedding of at least 80 known membrane-tethered proteins, which subsequently modulate several intracellular signaling pathways, and therefore alter cell behavior. Dysregulated expression and/or activation of ADAM17 has been linked to a wide range of autoimmune and inflammatory diseases, cancer, and cardiovascular disease. In this review, we provide an overview of the current state of knowledge from preclinical models and clinical data on the diverse pathophysiological roles of ADAM17, and discuss the mechanisms underlying ADAM17-mediated protein shedding and the potential therapeutic implications of targeting ADAM17 in these diseases.
蛋白酶 A 解整合素和金属蛋白酶 17(ADAM17)在多种疾病的病理生理学中发挥着核心作用。ADAM17 参与了至少 80 种已知的膜结合蛋白的切割和脱落,这些蛋白随后调节了几种细胞内信号通路,从而改变了细胞行为。ADAM17 的表达和/或激活失调与广泛的自身免疫和炎症性疾病、癌症和心血管疾病有关。在这篇综述中,我们从临床前模型和临床数据两方面概述了 ADAM17 的多样化病理生理学作用的现有知识,并讨论了 ADAM17 介导的蛋白脱落的机制以及针对这些疾病的 ADAM17 靶向治疗的潜在意义。